ONCYTE
OnCyte offers autologous CAR T-Cell drug candidate CM-CS1. CM-CS1 is an autologous CAR T-cell therapy which employs NKG2D, a “natural killer” cell receptor designed to target ligands present on most tumor types, including hematologic cancers as well as solid tumors. OnCyte’s portfolio also includes an allogeneic T-Cell platform designed to enable almost any CAR T-Cell therapy to be made into an “off-the-shelf” product. The platform is based on the engineering of T cells from healthy d... onors that, in addition to CAR, also express TCR Inhibitory Molecules. These molecules inhibit TCR function allowing the T cells to persist when injected into a patient. OnCyte’s CAR T-Cell technology is based on research by Charles L. Sentman, Ph.D., director of the Center for Synthetic Immunity and a professor of microbiology and immunity at Geisel School of Medicine at Dartmouth.
Similar Organizations
SaluTech
SaluTech develops a conductive biomaterial (CBM) to treat the underlying cause of arrhythmia.
More informations about "OnCyte"
onCyt Microbiology - Automated Microbial Monitoring
Founded in 2017, onCyt Microbiology AG is a spin-off of Eawag/ETH Zürich. The company emerged from a need to monitor microbes in drinking water around the clock, leading to the creation of the first fully automated online flow cytometer …See details»
OnCyte - Crunchbase Company Profile & Funding
OnCyte offers autologous CAR T-Cell drug candidate CM-CS1. CM-CS1 is an autologous CAR T-cell therapy which employs NKG2D, a “natural killer” cell receptor designed to target ligands …See details»
Our Team | Oncocyte
Meet our team of scientific and medical professionals that's leading the way to more efficient non-small cell lung cancer staging and treatment.See details»
Board of Directors – OncoCyte Corporation
Josh Riggs joined our Board of Directors and serves as our President and Chief Executive Officer since February 2023. Josh previously served as our Interim Chief Executive Officer since …See details»
Exploring Oncyte: A Portfolio Masterpiece by Lar’Rissa Scott
Jun 23, 2024 Introduction to Oncyte Oncyte, a distinguished portfolio piece created by Lar’Rissa Scott, serves as a testament to her innovative vision and technical prowess. Designed to …See details»
Oncyte Solutions
May 12, 2013 Oncyte Solutions is a recruiting firm that specializes exclusively in the recruitment and placement of clinical SAS programmers for the pharmaceutical industry throughout North …See details»
Virtici - OnCyte
Oncyte is focused on a portfolio of immuno-oncology CAR T cell therapies for cancer. Unlike traditional Chimeric Antigen Receptor (CAR) technologies, Oncyte’s therapies use the human …See details»
Oncology & Transplant Diagnostic …
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.See details»
Oncyte: A Masterpiece in Portfolio by Lar’Rissa Scott
Jun 23, 2024 The concept behind Oncyte was born out of a profound need for an efficient and user-friendly system to manage the voluminous data generated in cancer research and …See details»
Oncyte: A Portfolio Masterpiece by Lar’rissa Scott - OnCyte
Jun 23, 2024 Notably, Oncyte has received recognition in several design competitions, further establishing Lar’rissa Scott’s reputation as a talented and forward-thinking designer. Oncyte …See details»
Who We Are | Oncocyte
Unfortunately, cancer is a leading cause of death in the United States. Every year, employers, insurance companies, taxpayer-funded programs, and patients and their families spend more …See details»
Cardio3 Acquires OnCyte CAR T-Cell Portfolio — Celdara Medical
The acquisition marks Cardio3 Biosciences’ entry into the rapidly growing and very promising field of immuno-oncology, positioning the Company at the forefront of the CAR T-Cell space and …See details»
Celdara Medical Updates CAR-T Cell Agreement with Celyad
Celyad, a Belgium-based cell therapy company, obtained access to its CAR T cell drug product candidates and related technology in 2015 through its acquisition of OnCyte, LLC, a spin-out …See details»
Incyte - Biopharmaceutical Company | Solutions for Unmet …
Incyte is a global biopharmaceutical company focused on finding innovative solutions for serious unmet medical needs through the discovery, development and commercialization of novel …See details»
OnCyte LLC: Drug pipelines, Patents, Clinical trials - Synapse
Explore OnCyte LLC with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
Incyte Biosciences CANADA - Biopharmaceutical Company | Incyte.ca
Incyte is an international biopharmaceutical research company focused on creating proprietary therapeutics, oncology product development and innovative medicines to meet serious unmet …See details»
OncoCyte - Crunchbase Company Profile & Funding
OncoCyte is a biotech company helping save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer.See details»
Serving Patients Through Innovation | Incyte Stories
At Incyte, our passion for serving patients is what drives everything we do, and we are proud to be a global organization with in-house capabilities ranging from early discovery to manufacturing …See details»
ONCYTE Guide to Protein Microarrays - Grace Bio-Labs
Zation and capture of biomolecules. They have also been used in the manufacture of lateral flow immunoassays, such as pregnancy tests, in the diagnostic industry. The 3-dimensional …See details»
nitrocellulose slide membrane protein - BioCat
Highest standards in ONCYTE@ Nitrocellulose Slides ADVANCES IN NITROCELLULOSE MEMBRANE MICROARRAY TECHNOLOGY Twenty years ago, Grace Bio-Labs invented the …See details»